---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-323744"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:58:07.671029+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q3 2021 net loss $19.6M; cash $503.8M funds into H2 2024

## Summary
- Net loss of $19.6M ($0.28/share) vs $26.8M ($0.76) in Q3 2020; loss narrowed on revenue change.
- Cash, equivalents and marketable securities $503.8M; management expects to fund operations into H2 2024.
- Collaboration revenue was $6.8M vs negative $11.3M a year ago, due to Gilead amendment charge in Q3 2020.
- TNG908 IND on track for Q4 2021; Phase 1/2 trial initiation expected in H1 2022.
- Closed business combination with BCTG Acquisition Corp. and PIPE, yielding gross proceeds of $342M.

## SEC filing metadata
- accession: 0001193125-21-323744
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312521323744/0001193125-21-323744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312521323744/d256728d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-323744
- JSON: https://secwatch.observer/filing/0001193125-21-323744.json
- Plain text: https://secwatch.observer/filing/0001193125-21-323744.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.